As early as 2015, studies showed that glypican-1 is specifically enriched in EVs derived from cancer cells, so GPC1 circulating EVs can be used as a potential non-invasive diagnostic and screening tool for early pancreatic cancer [29]. Here, GPC1 is linked to pancreatic neoplasm.